• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    1/22/25 5:02:06 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    gdrx-20250121
    0001809519FALSE2701 Olympic BoulevardSanta MonicaCalifornia00018095192025-01-212025-01-21
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ________________________________________
    FORM 8-K
    ________________________________________
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): January 21, 2025
    ________________________________________
    GoodRx Holdings, Inc.
    (Exact Name of Registrant as Specified in its Charter)
    ________________________________________
    Delaware
    001-39549
    47-5104396
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)
    (IRS Employer
    Identification No.)
    2701 Olympic Boulevard
    Santa Monica, California
    90404
    (Address of Principal Executive
    Offices)
    (Zip Code)
    Registrant’s Telephone Number, Including Area Code: (855) 268-2822
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)
    ________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
    registrant under any of the following provisions:
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Class A Common Stock, $0.0001 par value per
    share
    GDRX
    The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
    of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
    period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
    Exchange Act. ☐
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
    Compensatory Arrangements of Certain Officers.
    On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the
    recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of
    the Company. Mr. Wagner’s term will expire at the Company’s 2025 Annual Meeting of Stockholders and until his successor
    is elected and qualified or until his earlier death, resignation or removal. The Board also appointed Mr. Wagner as the Chair
    of the Board’s Compensation Committee, and appointed Mr. Wagner as a Co-Chair of the Board, to serve in such role
    together with the existing Chair (now to be referred to as Co-Chair), Trevor Bezdek.
    Mr. Wagner, 53, served as the Company’s Interim Chief Executive Officer from April 2023 to January 2025. Mr. Wagner
    joins the Board with more than 25 years of executive leadership experience, including his tenure as Chief Executive Officer
    and President/Chief Operating Officer/Chief Financial Officer at GoDaddy, which saw the company expanded its services
    globally and tripling in revenue, reaching nearly $3 billion. Prior to GoDaddy, Mr. Wagner served as a Partner at KKR, a
    global investment company, where he worked from 2000 to 2012 as one of the leads of KKR’s Capstone team. Mr. Wagner
    holds a B.A. degree in Economics from Yale University and an M.B.A. degree from Harvard Business School. The Board
    believes Mr. Wagner is qualified to serve as a director due to his experience serving as Interim Chief Executive Officer of the
    Company, as well as his experience serving as a director and officer for high-growth tech companies.
    On January 21, 2025, Simon Patterson resigned as a member of the Board and as a member of the Board’s
    Nominating and Corporate Governance Committee and Innovation Committee. The vacancy created by Mr. Patterson’s
    resignation was filled by Mr. Wagner’s election. Mr. Patterson’s decision to resign is not the result of any disagreement with
    the Company or its management on any matter relating to the Company’s operations, policies or practices.
    The Company is party to that certain Stockholders Agreement, dated as of September 22, 2020 (the “Stockholders
    Agreement”), by and among the Company, SLP Geology Aggregator, L.P. (with certain affiliate stockholders, the “Silver Lake
    Stockholders”), an entity affiliated with Silver Lake, and certain other stockholders of the Company (collectively, together with
    the Silver Lake Stockholders, the “Sponsor Stockholders”), pursuant to which the Company granted each Sponsor
    Stockholder certain board designation rights subject to such Sponsor Stockholder’s ownership of specified percentages of
    the Company’s common stock. The Silver Lake Stockholders exercised their right under the Stockholders Agreement to fill
    the vacancy created by Mr. Patterson’s resignation. As discussed above, the Board’s Nominating and Corporate
    Governance Committee recommended, and the Board approved, the appointment of Mr. Wagner to fill the Class II vacancy.
    Mr. Wagner has entered into the Company’s standard indemnification agreement for directors and officers, the form of
    which was previously filed by the Company as Exhibit 10.1 to the Registration Statement on Form S-1/A (File No.
    333-248465) initially filed by the Company with the SEC on September 14, 2020.
    Compensation of Mr. Wagner
    Mr. Wagner will receive the standard compensation received by non-employee directors under the Company’s amended
    and restated Non-Employee Director Compensation Program (the “A&R Director Compensation Program”). Pursuant to the
    A&R Director Compensation Program, Mr. Wagner was granted an initial award of restricted stock units (“RSUs”) with a
    value of $420,000 and a pro-rated Annual Award (as defined below) of RSUs with a value of $85,699, in each case, effective
    on his Board election date. The number of RSUs underlying each award is determined by dividing the value by the average
    closing price for the Company’s Class A common stock over the 30 calendar days preceding the grant date. The initial award
    will vest as to one-third of the shares underlying the grant on each of the first three anniversaries of the grant date, subject to
    continued service through the applicable vesting date. The pro-rated Annual Award will vest in full on the earlier of (i) June 6,
    2025 and (ii) the date of the 2025 Annual Meeting of Stockholders, subject to continued service through the applicable
    vesting date. Under the A&R Director Compensation Program, Mr. Wagner also will be eligible to receive the following
    compensation as a non-employee director: (a) an annual cash retainer of $30,000 for his service on the Board (pro-rated
    based on his service during the 2025 fiscal year), (b) an additional annual cash retainer of $15,000 for his service as the
    Chair of the Compensation Committee (pro-rated based on his service during the 2025 fiscal year), and (c) if serving on the
    Board as of the date of the annual meeting of the Company’s stockholders for a given calendar year, an annual award of
    RSUs with a value of $230,000 (each, an “Annual Award”) granted on such annual meeting date.
    Pursuant to the Company’s Deferred Compensation Plan for Directors (the “Deferred Compensation Plan”), Mr. Wagner
    will be permitted to defer (i) all or a portion of his annual cash retainers (including any cash retainers for service on a
    committee) earned under the A&R Director Compensation Program and (ii) the settlement of any of his RSU awards granted
    under the A&R Director Compensation Program beyond the applicable vesting period in accordance with the terms and
    conditions set forth in the Deferred Compensation Plan.
    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report
    to be signed on its behalf by the undersigned hereunto duly authorized.
    GOODRX HOLDINGS, INC.
    Date:
    January 22, 2025
    By:
    /s/ Wendy Barnes
    Name: Wendy Barnes
    Title: Chief Executive Officer
    Get the next $GDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    1/22/2026$2.75Buy → Hold
    Jefferies
    12/9/2025$3.00Underweight
    Barclays
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Powers Pricing for Leading Brand Medications on TrumpRx

    Brief Summary: GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of Pfizer's essential brand medications spanning women's health, arthritis, and more By unifying pricing, pharmacy enablement, and a trusted consumer experience, GoodRx enables pharma manufacturers to rapidly deploy and scale emerging pricing models with minimal operational lift GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key integration partner for pharmaceutical companies offering discounted cash prices on T

    2/5/26 7:44:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Earns HITRUST i1 Certification for the Second Consecutive Year, Reinforcing Its Commitment to Protecting Healthcare Data at Scale

    Independent assessment validates GoodRx's continued leadership in cybersecurity and data protection GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its 2026 certification status for HITRUST i1 Certification for its prescription savings platform hosted on Amazon Web Services (AWS). This certification shows continuous dedication to GoodRx's prior HITRUST achievement and underscores the company's ongoing commitment to safeguarding sensitive healthcare information. The HITRUST i1 Certification demonstrates that GoodRx has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that strong controls

    2/2/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

    GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., to offer eligible co

    2/2/26 8:01:00 AM ET
    $GDRX
    $SXTP
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Mcginnis Christopher A covered exercise/tax liability with 52,799 shares and converted options into 179,120 shares (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/17/26 5:26:05 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 4,804 shares and covered exercise/tax liability with 1,979 shares, increasing direct ownership by 2% to 175,748 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/17/26 5:25:25 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 5,215 shares, increasing direct ownership by 5% to 172,923 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    2/9/26 5:49:36 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Jefferies with a new price target

    Jefferies downgraded GoodRx from Buy to Hold and set a new price target of $2.75

    1/22/26 8:25:34 AM ET
    $GDRX
    EDP Services
    Technology

    Barclays initiated coverage on GoodRx with a new price target

    Barclays initiated coverage of GoodRx with a rating of Underweight and set a new price target of $3.00

    12/9/25 8:49:54 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    SEC Filings

    View All

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    12/12/25 4:26:49 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:31:17 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    11/4/25 4:23:32 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Financials

    Live finance-specific insights

    View All

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2025 Results

    Company Maintains Full Year 2025 Revenue and Adjusted EBITDA Expectations; Raises Pharma Manufacturer Solutions Revenue Outlook to Approximately 35% Year-Over-Year Growth for 2025 GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025. Third Quarter 2025 Highlights Revenue of $196.0 million Net income of $1.1 million; Net income margin of 0.6% Adjusted Net Income1 of $28.8 million; Adjusted Net Income Margin1 of 14.7% Adjusted EBITDA1 of $66.3 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of

    11/4/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after U.S. markets close on Tuesday, November 4, 2025. GoodRx management will also hold a conference call and webcast the following morning, Wednesday, November 5, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To participate via telephone, please call (800) 715-9871 at least 10 minutes before the conference call is scheduled to begin. The conference ID is 9085550. The call will also be webcast live on the Company's investor relat

    10/8/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology